Veradermics, Inc
MANENext catalyst
VDPHL01
Androgenetic Alopecia
Get an email about MANE's next catalysts
Track Veradermics (MANE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 3 readout).See the timeline
3 upcoming, 0 past
MANE Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.59 | FQ end Sep/2026 | Call: tbd
VDPHL01 Phase 3 Est. Readout
Primary completion for VDPHL01 trial (NCT06972264) in Androgenetic Alopecia
SourceVDPHL01 QD Phase 3 Est. Readout
Primary completion for VDPHL01 QD trial (NCT07146022) in Androgenetic Alopecia (AGA)
SourceMarket Overview
Stock performance and key metrics
VDPHL01
Androgenetic Alopecia
VDPHL01 QD
Androgenetic Alopecia (AGA)
VDPHL01 BID
Androgenetic Alopecia (AGA)
VDMN-21 Patch Low Dose
Verruca Vulgaris
VDMN-21 Patch High Dose
Verruca Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VDPHL01 | Phase 3 | Androgenetic Alopecia | - | - |
VDPHL01 QD | Phase 3 | Androgenetic Alopecia (AGA) | - | - |
VDPHL01 BID | Phase 3 | Androgenetic Alopecia (AGA) | - | - |
VDMN-21 Patch Low Dose | Phase 2 | Verruca Vulgaris | - | - |
VDMN-21 Patch High Dose | Phase 2 | Verruca Vulgaris | - | - |
Frequently asked questions
What is in Veradermics, Inc's drug pipeline?→
CatalystAlert tracks 5 drug candidates in Veradermics, Inc's (MANE) pipeline across Phase 3, Phase 2. Its lead program is VDPHL01 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Veradermics, Inc's next FDA catalyst?→
Veradermics, Inc's (MANE) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MANE biotech catalysts?→
Add MANE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Veradermics, Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.